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ABSTRACT
Objectives Assess golimumab’s long-term efﬁcacy/
safety in psoriatic arthritis (PsA).
Methods Adults with active PsA (≥3 swollen and
tender joints, active psoriasis) were randomly assigned to
subcutaneous placebo, golimumab 50 mg, or golimumab
100 mg every 4 weeks (q4wks) through wk20. All
patients received golimumab 50 mg or 100 mg q4wks
from wk24 forward. Methotrexate was allowed and
taken by approximately half the patients. Findings
through 5 years are reported herein. Efﬁcacy assessments
included ≥20% improvement in American College of
Rheumatology (ACR20) response, C-reactive-protein-
based, 28-joint-count Disease Activity Score (DAS28-
CRP) response, ≥75% improvement in Psoriasis Area
and Severity Index (PASI75) scores, and PsA-modiﬁed
Sharp/van der Heijde scores (SHSs).
Results 126/405 (31%) randomised patients
discontinued treatment through wk252. Golimumab was
effective in maintaining clinical improvement through
year-5 (ACR20: 62.8–69.9%, DAS28-CRP: 75.2-84.9%
for randomised patients; PASI75: 60.8–72.2% among
randomised patients with ≥3% body surface area
involvement) and inhibiting radiographic progression
(mean changes in PsA-modiﬁed SHS: 0.1–0.3) among
patients with radiographic data. While concomitant
methotrexate did not affect ACR20/PASI75, it appeared to
reduce radiographic progression. No new safety signals
were identiﬁed. Antibodies-to-golimumab occurred in
1.8%/10.0% of patients with/without methotrexate).
Conclusions Long-term golimumab safety/efﬁcacy in
PsA was demonstrated through 5 years.
Trial registration number NCT00265096.
Biologic anti-tumour necrosis factor-α (TNF) agents
have demonstrated efﬁcacy in psoriatic arthritis (PsA),
in treating arthritic/dermatologic symptoms and inhi-
biting structural damage progression.1–5 The human
anti-TNF monoclonal antibody golimumab (50/
100 mg subcutaneously every 4 weeks (q4wks)) was
evaluated in the GO-REVEAL Phase 3, randomised,
double-blind, placebo-controlled trial in 405 patients
with active PsA (NCT00265096). Study results
through wk24 (placebo-controlled), wk52, and
wk104 have been published.6–8 We now provide a
ﬁnal report of efﬁcacy and safety data in PsA patients
receiving golimumab through 5 years.
PATIENTS AND METHODS
Details of patient eligibility criteria, study design, and
study endpoints have been reported.6–8 Brieﬂy,
patients were naive to anti-TNF therapy, had active
PsA (≥3 swollen, ≥3 tender joints), and had plaque
psoriasis (qualifying lesion diameter ≥2 cm) despite
therapy with disease-modifying antirheumatic or
non-steroidal anti-inﬂammatory drugs. Concomitant
methotrexate was allowed but not required. Study
design and analytical details speciﬁc to the
GO-REVEAL long-term extension (LTE) are pro-
vided online.
RESULTS
Patient disposition and baseline characteristics
Four hundred and ﬁve patients were randomised
and treated. Consent was obtained for the ﬁrst
patient on 12 December 2005; the last patient com-
pleted wk268 (16 weeks after last study injection)
on 13 January 2012. Patient disposition through
wk24,6 wk527 and wk1048 have been reported.
Among the 405 randomised patients, 126 (31%) dis-
continued study treatment through wk252 (see
online supplementary table S1). Radiographic
images/scores were available for 304 patients at base-
line and wk104 and for 267 patients at wk256. For
details of baseline patient and disease characteristics
and concomitant medications, see online tables S1,
S2, S3, and supplemental material.
Efﬁcacy results
Among randomised patients, wk256 response rates
were 62.8–69.9%, 43.4–50.7% and 30.8–35.6%
for American College of Rheumatology ≥20%/
50%/70% improvement criteria (American College
of Rheumatology, ACR20, ACR50 and ACR70,
respectively; ﬁgure 1A). No consistent differences
in ACR response by baseline methotrexate use were
observed (ﬁgures 1B,C). Mean C-reactive-protein-
based, 28-joint-count Disease Activity Scores
(DAS28-CRP) at wk256 were 2.8–3.0 versus
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baseline scores of 4.9–5.0 (table 1). DAS28-CRP responses and
improvements in dactylitis and enthesitis scores are also sum-
marised in table 1.
At least 75% improvement in the Psoriasis Area and Severity
Index (PASI75) (ﬁgure 1D) was achieved at wk256 in 60.8–72.2%
of randomised patients with baseline psoriasis involving ≥3%
body surface area. No consistent differences in PASI responses by
baseline methotrexate use were observed (ﬁgures 1E,F).
Improvements in nail psoriasis severity were also evident (table 1).
Clinically meaningful improvements in physical function
(Health Assessment Questionnaire Disability Index (HAQ-DI)
decrease ≥0.3)9 were observed at wk256 for 52–58% of rando-
mised patients. Mean wk256 HAQ-DI scores were 0.6–0.7
versus baseline scores of 1.0–1.1. Patients also experienced
improvement in health-related quality of life (table 1).
The two radiographic readers demonstrated good agreement
in radiographic image scoring (see online supplementary mater-
ial). At wk256, observed changes (mean±SD) from baseline in
PsA-modiﬁed radiographic scores were 0.3±3.8, 0.3±4.2, and
0.1±2.7 in the placebo, 50 mg and 100 mg groups, respectively
(table 1, see online supplementary ﬁgure S1A). Patients receiving
methotrexate at baseline demonstrated numerically less progres-
sion at wk256 than patients not receiving methotrexate based
on mean changes in Sharp/van der Heijde score (SHS) (table 1,
see online supplementary ﬁgures S1B,C). Estimated annual
radiographic progression, calculated as baseline total score
divided by baseline PsA duration, was markedly reduced over
5 years (see online supplementary ﬁgure S2).
The effect of golimumab dose escalation from 50 mg q4wks
to 100 mg q4wks was evaluated for patients who had not
achieved DAS28-CRP <2.6 or PASI75 response before dose
escalation. Increasing the golimumab dose yielded approxi-
mately 18% and 44% improvement in DAS28-CRP and PASI
scores, respectively (table 1).
For details of golimumab pharmacokinetic and antibody
assessments, please see online supplementary materials.
Antibodies-to-golimumab developed in 6% (20/335), including
1.8% (3/165) and 10.0% (17/170), respectively, of patients
receiving and not receiving methotrexate at baseline.
Safety results
Per protocol, no patient received placebo beyond wk24. In
general, no differences in the types of adverse events (AE) were
observed between golimumab doses (table 2). See online supple-
mentary material for summaries of AEs reported after initiation
of commercial drug, injection-site reactions, and clinical labora-
tory ﬁndings.
AEs leading to discontinuation observed in >1 golimumab-
treated patient overall included basal cell carcinoma (basal cell
carcinoma (BCC), 3–50 mg, 2–50+100 mg, 3–100 mg patients),
increased alanine aminotransferase (5–50 mg, 1–50+100 mg),
increased aspartate aminotransferase (3–50 mg, 1–50+100 mg),
psoriatic arthropathy (1–50 mg, 2–50+100 mg), breast cancer
(2–50 mg), and accidental death (1–50 mg, 1–100 mg).
Five patients died through wk268 (50 mg-climbing accident,
50 mg-small-cell lung cancer, 100 mg motor bike accident,
100 mg oesophageal cancer, 100 mg unknown cause).
Serious AEs observed in >1 golimumab-treated patient
included 10 patients with BCC; ﬁve patients with myocardial
infarction; three patients with cholelithiasis; and two patients
each with breast cancer, abscess, cellulitis, pneumonia, arthritis,
intervertebral disc degeneration, upper abdominal pain,
Figure 1 The proportions of patients achieving clinical improvement at week 256, deﬁned by at least 20%, 50% and/or 70% improvement in the
American College of Rheumatology response criteria (ACR20, ACR50 and ACR70, respectively; A–C) or at least 50%, 75% and/or 90% improvement
in the Psoriasis Area and Severity Index response criteria (PASI50, PASI75 and PASI90, respectively) among randomised patients with baseline
psoriasis involving ≥3% body surface area (D–F) among all patients (A, D) patients with methotrexate (MTX) use at baseline (B, E), and patients
with no MTX use at baseline (C, F). Analyses were based on intent-to-treat analyses by randomised group, irrespective of treatment changes during
the study. The placebo group includes patients who were initially randomised to placebo and later early escaped/crossed over at week 16/24 to
receive golimumab 50 mg, with the possibility to increase golimumab from 50 to 100 mg after the week-52 database lock. The golimumab 50 mg
group includes patients who were initially randomised to golimumab 50 mg and later early escaped at week 16 or dose escalated after the week 52
database lock to receive golimumab 100 mg. All patients could decrease the golimumab dose from 100 to 50 mg after the week-52 database lock.
1690 Kavanaugh A, et al. Ann Rheum Dis 2014;73:1689–1694. doi:10.1136/annrheumdis-2013-204902
Clinical and epidemiological research
 group.bmj.com on September 29, 2014 - Published by ard.bmj.comDownloaded from 
Table 1 Summary of efficacy and concomitant medication use at week 256 by randomised treatment group
Golimumab
Placebo* 50 mg† 100 mg‡
Number of randomised patients 113 146 146
Radiographic efficacy at week 256 (among patients with SHS at weeks 0, 104, and 256)
CHANGE in modified SHS
Total score, N= 73 93 101
0.3±3.8 0.3±4.2 0.1±2.7
0.0 (−0.5, 0.5) 0.0 (−0.5, 1.0) 0.0 (0.0, 1.0)
MTX use at baseline, N= 43 48 52
0.0±2.2 −0.3±4.8 −0.3±3.4
0.0 (−1.0, 1.0) 0.0 (−1.5, 0.5) 0.0 (−0.5, 0.5)
No MTX use at baseline, N= 30 45 49
0.7±5.4 0.9±3.3 0.4±1.8
0.0 (0.0, 0.5) 0.0 (0.0, 1.5) 0.0 (0.0, 1.0)
Erosion score, N= 73 93 101
−0.1±3.1 −0.03±2.8 −0.3±1.9
0.0 (−0.5, 0.0) 0.0 (−0.5, 0.5) 0.0 (0.0, 0.5)
Joint space narrowing score, N= 73 94 101
0.4±1.4 0.3±1.9 0.4±1.4
0.0 (0.0, 0.5) 0.0 (0.0, 0.5) 0.0 (0.0, 0.5)
Pts with change in total PsA-modified SHS ≤0 (%) 46/73 (63.0) 58/93 (62.4) 66/101 (65.3)
Clinical efficacy at week 256 (intent-to-treat analysis by randomised treatment group)
DAS28-CRP, N = 113 146 146
Baseline score 4.9±1.0 5.0±1.1 4.9±1.1
Week 256 score 3.0±1.4 2.8±1.2 2.8±1.2
DAS28-CRP responder (good/moderate) (%) 85 (75.2) 122 (83.6) 124 (84.9)
% improvement in DAS28-CRP score 12 weeks after DE among pts who had not achieved
a DAS28-CRP score < 2.6 before DE§
– – N=47
18.0±21.2%
Enthesitis, ¶ N = 88 109 115
Baseline score 5.0±4.1 5.7±4.0 6.1±4.1
Week 256 score 2.4±4.0 1.9±3.3 2.0±3.4
Dactylitis,** N = 38 50 49
Baseline score 3.1±2.1 6.3±6.1 5.4±6.7
Week 256 score 1.2±2.3 1.3±4.9 0.8±2.1
HAQ-DI, N= 113 146 146
Baseline score 1.0±0.5 1.0±0.6 1.1±0.6
Week 256 score 0.7±0.6 0.6±0.6 0.6±0.6
Pts with HAQ-DI improvement ≥0.3 units 59 (52.2%) 79 (54.1%) 85 (58.2%)
PASI,†† N= 79 109 108
Baseline score 8.4±7.4 9.8±8.6 11.1±9.5
Week 256 score 3.0±5.8 2.7±4.5 2.2±3.9
% improvement in PASI score 12 weeks after DE among pts without PASI75
response before DE§
– – n=16
44.3±35.4%
NAPSI,‡‡ N= 83 95 109
Baseline score 4.4±2.2 4.7±2.2 4.6±2.1
Week 256 score 1.1±1.9 1.7±2.5 1.1±1.8
SF-36 PCS score, N= 113 146 146
Score 40.1±11.4 41.8±11.6 41.0±11.1
Improvement from baseline 8.1±10.9 8.8±11.1 8.2±11.0
SF-36 MCS score, N= 113 146 146
Score 50.9±10.1 49.5±10.4 49.6±10.6
Improvement from baseline 3.3±11.1 4.2±11.8 4.5±11.2
Concomitant medication use at wk256
MTX (%) 46 (40.7) 59 (40.4) 73 (50.0)
Dose (prednisone equivalent mg/week) 15.2±4.6 13.6±4.6 14.2±4.5
Oral corticosteroids (%) 16 (14.2) 17 (11.6) 21 (14.4)
Prednisone-equivalent dose (mg/day) 6.1±2.1 7.5±2.9 7.5±8.2
NSAIDs (%) 68 (60.2) 93 (63.7) 98 (67.1)
Data shown are mean±SD, median (IQR) or number (%) of patients at week 256, unless otherwise specified.
*Includes patients who were initially randomised to placebo and later early escaped at week 16 or crossed over at week 24 to receive golimumab 50 mg, with the possibility after the
week-52 database lock to increase the golimumab dose to 100 mg and also to decrease the golimumab dose from 100 mg to 50 mg.
†Includes patients who were initially randomised to golimumab 50 mg and later early escaped at week 16 or dose escalated after the week-52 database lock to receive golimumab
100 mg, with the possibility to decrease the dose from 100 mg to 50 mg after the week-52 database lock.
‡Includes patients randomised to receive golimumab 100 mg at week 0, with the possibility to decrease the golimumab dose from 100 mg to 50 mg after the week-52 database lock.
§Dose-escalation analyses used data from week 0 to 256, that is, from blinded and open-label portions of the study, from patients who had ≥12 weeks of follow-up after dose
escalation.
¶Among patients with enthesitis at baseline.
**Among patients with dactylitis at baseline.
††Among patients with ≥3% BSA involvement at baseline.
‡‡Among patients with nail involvement at baseline.
BSA, body surface area; DAS28-CRP, C-reactive protein-based, 28-joint-count Disease Activity Score; HAQ-DI, Health Assessment Questionnaire Disability Index; DE, dose escalation from
golimumab 50 mg q4w to golimumab 100 mg q4w; MCS, mental component summary; MTX, methotrexate; NAPSI, Nail Psoriasis Activity Index; NSAIDs, nonsteroidal anti-inflammatory
drugs; PASI, Psoriasis Area and Severity Index; PCS, physical component summary; PsA, psoriatic arthritis; SF-36, 36-item short-form health survey, SHS, Sharp/van der Heijde score.
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vomiting, tibia fracture, accidental death, chest pain and superﬁ-
cial thrombophlebitis. Fifteen patients developed serious infec-
tions through wk268, with similar incidences across treatment
groups. Few patients developed opportunistic infections, includ-
ing one patient each with pulmonary tuberculosis plus legionella
pneumonia, histoplasmosis and eye toxoplasmosis, all while
receiving golimumab 100 mg. A patient receiving golimumab
100 mg developed non-serious herpes zoster involving the eye.
The incidence of major adverse cardiovascular events
(MACE) through wk268 was similar across all treatment groups
(table 2). Beyond MACE events, two golimumab patients (1–
50 mg+100 mg, 1–100 mg only) had congestive heart/ventricu-
lar failure through wk268.
Malignancies were documented for 21 patients through
wk268, including 10 patients with non-melanoma skin cancer
(NMSC, 1 squamous cell+basal cell, 9 basal cell) and 11 with
other non-lymphoma malignancies that included breast (2–
50 mg), bladder (1–50+100 mg, 1–100 mg), colon (2–50 mg,
1–100 mg), oesophageal (1–100 mg), prostate (1–100 mg), and
small-cell lung (1–50 mg, 1–100 mg) cancers. The incidences of
malignancies per 100 patient-years are presented in table 2. In
an analysis comparing incidences of malignancies (excluding
NMSC) observed in GO-REVEAL and expected rates in the
general US population,10 the standard incidence ratios ranged
from 0.57 to 1.85 (table 2).
DISCUSSION
We previously reported golimumab (subcutaneous 50 and
100 mg q4wks) efﬁcacy/safety in patients with active PsA.
Golimumab-treated patients displayed signiﬁcant and/or
Table 2 Summary of safety through week 268
Golimumab*
50 mg only 50 and 100 mg 100 mg only Total
Number of golimumab-treated pts 139 146 109 394
Mean weeks of follow-up 190.0 242.1 217.3 216.9
Mean number of administrations 44.3 56.9 51.1 50.9
Pts with ≥1 AE (%) 121 (87.1) 126 (86.3) 100 (91.7) 347 (88.1)
Pts with ≥1 serious AE (%) 29 (20.9) 29 (19.9) 25 (22.9) 83 (21.1)
Pts who discontinued study (%) agent because of AE 21 (15.1) 9 (6.2) 19 (17.4) 49 (12.4)
Pts with ≥1 infection (%) 94 (67.6) 100 (68.5) 87 (79.8) 281 (71.3)
Death
Pts with event (%) 2 (1.4) 0 3 (2.8) 5 (1.3)
Incidence/100 pt-yrs (95% CI) 0.39 (0.05 to 1.42) 0.00 (0.00 to 0.44) 0.66 (0.14 to 1.92) 0.30 (0.10 to 0.71)
Serious infection
Pts with event (%) 5 (3.6) 4 (2.7) 6 (5.5) 15 (3.8)
Number of serious infections 5 7 7 19
Incidence/100 pt-yrs (95% CI) 0.98 (0.32 to 2.30) 1.03 (0.41 to 2.12) 1.54 (0.62 to 3.17) 1.16 (0.70 to 1.81)
MACE†
Pts with event (%) 4 (2.9) 4 (2.7) 3 (2.8) 11 (2.8)
Number of MACE 5 4 4 13
Incidence/100 pt-yrs (95% CI) 0.98 (0.32 to 2.30) 0.59 (0.16 to 1.51) 0.88 (0.24 to 2.25) 0.79 (0.42 to 1.35)
All malignancies
Pts with event 8 5 8 21
Incidence/100 pt-yrs (95% CI) 1.58 (0.68 to 3.12) 0.74 (0.24 to 1.72) 1.77 (0.77 to 3.49) 1.28 (0.80 to 1.96)
SIR (95% CI) relative to SEER (excluding NMSC) 1.85 (0.60 to 4.32) 0.57 (0.07 to 2.05) 1.42 (0.39 to 3.64) 1.22 (0.61 to 2.18)
Type of malignancies
Pts with lymphoma 0 0 0 0
Pts with NMSC 3 3 4 10
Incidence/100 pt-yrs (95% CI) 0.59 (0.12 to 1.73) 0.44 (0.09 to 1.29) 0.88 (0.24 to 2.25) 0.61 (0.29 to 1.12)
Pts with other malignancies (excluding NMSC) 5 2 4 11
Incidence/100 pt-yrs (95% CI) 0.99 (0.32 to 2.30) 0.29 (0.04 to 1.06) 0.88 (0.24 to 2.26) 0.67 (0.34 to 1.20)
SIR (95% CI) relative to SEER 1.94 (0.63 to 4.52) 0.60 (0.07 to 2.16) 1.49 (0.41 to 3.81) 1.28 (0.64 to 2.28)
Golimumab injection-site reactions
Pts with reactions (%) 14 (10.1) 8 (5.5) 15 (13.8) 37 (9.4)
Injections with reactions (%) 51/6158 (0.8) 11/8314 (0.1) 31/5572 (0.6) 93/20044 (0.5)
Number of pts with >1 markedly abnormal postbaseline value
for most commonly observed abnormalities through wk256
139 146 109 394
Elevated eosinophil count‡ (%) 3 (2.2) 3 (2.1) 2 (1.8) 8 (2.0)
Elevated total bilirubin§ (%) 5 (3.6) 5 (3.4) 1 (0.9) 11 (2.8)
Data shown are number (%) of patients, unless otherwise specified.
*With or without methotrexate.
†MACE were defined as cardiovascular deaths or cardio/cerebrovascular serious AEs and included acute myocardial infarction/ischemia, aphasia, carotid artery stenosis/disease/occlusion,
death.
‡Markedly increased eosinophil count defined as ≥100% increase and value >0.8×103/mL.
§Markedly elevated total bilirubin value defined as ≥100% increase and value >1.5 mg/dL.
AE, adverse event; MACE, major adverse cardiovascular event; NMSC, non-melanoma skin cancer; pt(s), patient(s); pt-yrs, patient-years; SEER, Surveillance, Epidemiology and End
Results database; SIR, standardised incidence ratio (observed/expected based on the SEER database (2004)), adjusted for age, gender, and race).
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clinically meaningful improvements in all aspects of PsA versus
placebo.6 7 Despite no control arm, ﬁndings through wk104 of
the LTE also supported golimumab’s clinical and radiographic
beneﬁts.8 The current report extends the golimumab experience
by 3 years, representing the longest available clinical trial data of
chronic anti-TNF treatment of PsA patients.
The GO-REVEAL trial retained more than two-thirds of ran-
domised patients through 5 years, and although lacking a
control after wk24, data through 5 years provide further insight
into golimumab efﬁcacy and safety. At the last efﬁcacy evalu-
ation (wk256; assessed with intent-to-treat (ITT) methodology),
63–70% and 43–51% of patients across randomised groups
were ACR20 and ACR50 responders, respectively, and mean
baseline DAS28-CRP scores decreased from 4.9–5.0 to <3.2
across treatment groups. Meaningful improvements were also
noted in physical function, enthesitis, dactylitis, and skin mani-
festations, including >60% of patients achieving PASI75
improvement at wk256. Importantly, minimal changes in radio-
graphic scores occurred from baseline to wk256 (mean change
in total SHS ≤0.3), suggesting a long-term effect of golimumab
on inhibiting radiographic progression.
No meaningful differences in efﬁcacy outcomes were
observed between the 50 mg and 100 mg doses of golimumab
administered q4wks; however, analyses were limited by allowed
dose changes. Similarly, analyses of clinical response in arthritis
and psoriasis after dose escalation from 50 to 100 mg q4wks
suggesting improved efﬁcacy, especially in PASI scores, were
limited by lack of a control arm. Golimumab dose escalation
occurred in approximately one-quarter of randomised patients
and, given low discontinuation rates due to lack of golimumab
efﬁcacy, likely reﬂects a treat-to-target therapeutic approach in
patients with residual disease activity.
Golimumab safety through 5 years was also consistent with
those observed previously in this PsA patient population.6–8
Serious infections occurred in 15 patients; a limited number of
patients had opportunistic infections, all while receiving golimu-
mab 100 mg. The incidence of antibodies to golimumab was
low across the golimumab treatment groups and did not appear
to affect injection-site-reaction development. Consistent with
earlier observations,6–8 fewer methotrexate-treated than
untreated patients developed antibodies to golimumab. The inci-
dences of all malignancies excluding NMSC observed in
GO-REVEAL did not differ from those expected in the general
US population. No meaningful differences in safety outcomes
were observed between patients receiving golimumab 50 mg,
100 mg, or both doses, except opportunistic infections (all
reported for golimumab 100 mg).
Limitations of long-term data presented herein include the
lack of a long-term control arm and golimumab dose changes,
restricting the ability to compare golimumab 50 mg with
100 mg. To compensate for such limitations, clinical efﬁcacy
data were evaluated on an ITT basis (randomised patients with
imputation for missing data). However, to avoid imputation of
radiographic data, radiographic analyses were based on patients
who had available images at baseline/wk104/wk256, comprising
∼66% of randomised patients. Although radiographic analyses
including patients with available data are possibly biased by
including responders only, the alternative analyses employing
all patients and imputation methodologies rely on assumptions
made for patients with missing data, also possibly leading to
biased estimates of radiographic progression. Baseline disease
characteristics were similar between the radiographic patient
subset and all randomised patients, indicating ﬁndings may be
applicable to the overall study population.
Despite discussed limitations, the safety and efﬁcacy of goli-
mumab 50 mg and 100 mg administered subcutaneously q4wks
to patients with active PsA were demonstrated through 5 years,
as evidenced by sustained clinical and radiographic efﬁcacy and
a safety proﬁle consistent with other anti-TNF agents used for
PsA.11
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